(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 18.43% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.25%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.49%.
Xeris Biopharma Holdings's revenue in 2025 is $246,025,000.On average, 4 Wall Street analysts forecast XERS's revenue for 2025 to be $46,373,124,393, with the lowest XERS revenue forecast at $45,941,164,412, and the highest XERS revenue forecast at $46,683,974,100. On average, 4 Wall Street analysts forecast XERS's revenue for 2026 to be $56,465,647,331, with the lowest XERS revenue forecast at $53,708,370,064, and the highest XERS revenue forecast at $59,376,330,946.
In 2027, XERS is forecast to generate $65,871,878,708 in revenue, with the lowest revenue forecast at $60,377,509,221 and the highest revenue forecast at $73,570,455,205.